Evidence map›Paper›PMID 36816616›Full record

ArticleNeurobiology of pain (Cambridge, Mass.)

Modulating the activity of human nociceptors with a SCN10A promoter-specific viral vector tool.

Stephanie Mouchbahani-Constance, Camille Lagard, Justine Schweizer, Isabelle Labonté, Miltiadis Georgiopoulos, Colombe Otis, Manon St-Louis, Eric Troncy, Philippe Sarret, Alfredo Ribeiro-Da-Silva and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of pain (Cambridge, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Stephanie Mouchbahani-ConstanceDepartment of Physiology and Cell Information Systems Group, McGill University, Montreal, Canada.
Camille LagardInstitut de Pharmacologie de Sherbrooke, Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Justine SchweizerAlan Edwards Center for Research on Pain, McGill University, Montreal, Canada.
Isabelle LabontéCERVO Brain Research Centre, CIUSSS-CN, Quebec, Quebec, Canada.
Miltiadis GeorgiopoulosSpine Surgery Program, Department of Surgery, McGill University, Montreal, Canada.
Colombe OtisResearch Group in Animal Pharmacology of Quebec (GREPAQ), Université de Montréal, Saint-Hyacinthe, Quebec, Canada.
Manon St-LouisDepartment of Pharmacology & Therapeutics, McGill University, Montreal, Quebec, Canada.
Eric TroncyResearch Group in Animal Pharmacology of Quebec (GREPAQ), Université de Montréal, Saint-Hyacinthe, Quebec, Canada.
Philippe SarretInstitut de Pharmacologie de Sherbrooke, Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Alfredo Ribeiro-Da-SilvaAlan Edwards Center for Research on Pain, McGill University, Montreal, Canada.
Jean A OuelletAlan Edwards Center for Research on Pain, McGill University, Montreal, Canada.
Philippe SéguélaAlan Edwards Center for Research on Pain, McGill University, Montreal, Canada.
Marie-Eve PaquetCERVO Brain Research Centre, CIUSSS-CN, Quebec, Quebec, Canada.
Reza Sharif-NaeiniDepartment of Physiology and Cell Information Systems Group, McGill University, Montreal, Canada.
McGill University · CACentre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal · CAQuebec - Clinical Research Organization in Cancer · CAUniversité de Montréal · CAMontreal Neurological Institute and Hospital · CAUniversité de Sherbrooke · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the high prevalence of chronic pain as a disease in our society, there is a lack of effective treatment options for patients living with this condition. Gene therapies using recombinant AAVs are a direct method to selectively express genes of interest in target cells with the potential of, in the case of nociceptors, reducing neuronal firing in pain conditions. We designed a recombinant AAV vector expressing cargos whose expression was driven by a portion of the SCN10A (Na

Indexed as

AAVChemogeneticsDREADDDRGGene therapyPainSodium channel

Identifiers

PMID36816616
PMCPMC9932673
OpenAlexW4318473531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.